NCT06146101Phase 2, phase 3Completed

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-05-20Actual

Enrollment · participants121Actual

Source updated2026-07-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-27 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~560 participants (planned)~~

+ After

121 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Dec 2026~~

+ After

20 May 2025

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Obstructive Sleep Apnea

Treatments or interventions studied

IHL-42X Low DoseDrugAlso known as Phase 2 Investigational Product - IHL-42X Low dose
IHL-42X High DoseDrugAlso known as Phase 2 Investigational Product - IHL-42X High dose
PlaceboDrugAlso known as Phase 2 Placebo
IHL-42X (Optimal Dose)DrugAlso known as Phase 3 Investigational Product - IHL-42X
DronabinolDrugAlso known as Phase 3 Comparator - Reference Listed Drug/Dronabinol
AcetazolamideDrugAlso known as Phase 3 Comparator - Reference Listed Drug/Acetazolamide
PlaceboDrugAlso known as Phase 3 Placebo

Primary outcomes · main study measures

measure: Change in apnea-hypopnea index (AHI); description: Phase 2 - Assess the change in AHI compared to baseline; timeFrame: 4 weeks; measure: Change in apnea-hypopnea index (AHI); description: Phase 3 - Assess the change in AHI compared to baseline; timeFrame: 52 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history